Silvia K.
- Country
- Germany
- Department
- Klinik für Gynäkologie und Geburtshilfe
Research Overview
Specializations
Breast Cancer Therapeutics
Focuses on targeted and immuno‑based strategies for hormone‑receptor positive and triple‑negative breast cancer.
- Adjuvant ribociclib plus endocrine therapy
- Neoadjuvant pembrolizumab with chemotherapy
- Sacituzumab Govitecan for residual disease
- Olaparib in germline BRCA‑mutated tumors
- Abemaciclib in high‑risk early stage disease
Emphasizes integration of CDK4/6 inhibition, PARP inhibition, and checkpoint blockade to improve invasive disease‑free survival.
NSCLC Innovation
Investigates molecularly defined subgroups of advanced NSCLC including KRAS G12C and atypical EGFR mutations.
- KRAS G12C inhibitors combined with pembrolizumab
- Osimertinib plus chemotherapy for atypical EGFR alterations
- MCLA‑129 bispecific antibody
- Sacituzumab Govitecan in squamous histology
- Domvanalimab and zimberelimab with chemotherapy
Aims to extend progression‑free survival through genotype‑directed combos.
Gynecologic Oncology
Targets high‑grade epithelial ovarian, fallopian tube and primary peritoneal malignancies.
- Adjuvant durvalumab plus olaparib
- Platinum‑bevacizumab backbone with immunotherapy
- Neoadjuvant chemotherapy optimization
- Biomarker‑driven HRD‑positive strategies
- Organ preservation approaches in advanced disease
Seeks to improve overall survival and quality of life in advanced gynecologic cancers.
Hematologic Malignancies
Engages in novel approaches for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Lisaftoclax combined with a BTK inhibitor
- BTK inhibitor sequencing strategies
- PRAME‑targeted bispecific TCER
- Safety profiling of emerging agents
- Combination immunotherapy regimens
Focuses on achieving deeper responses while maintaining tolerability.
Multimodal Solid Tumor Strategies
Explores integration of radiotherapy, immunotherapy, and targeted agents across diverse solid tumors.
- Hypofractionated thoracic radiotherapy with durvalumab
- Organ preservation in rectal cancer using selective chemoradiotherapy
- Volrustomig as monotherapy or in combination
- Combination of chemotherapy with checkpoint blockade
- Adjuvant ribociclib without prior chemotherapy
Prioritizes treatment de‑intensification and quality‑of‑life outcomes.
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.